What Is TB-500? What the Research Actually Shows

What is TB-500, and what does the evidence show?

TB-500 is a synthetic Ac-LKKTETQ heptapeptide, the seven-residue fragment corresponding to residues 17–23 of thymosin beta-4 (Tβ4), with a molecular mass of about 889 Da.⁵ Tβ4 is a different, full-length 43-amino-acid protein of about 4,963 Da. Research on full-length Tβ4 cannot automatically be applied to TB-500. The FDA reports no identified human exposure data for products containing the fragment and says important safety questions remain unanswered.⁵

Start with the name: TB-500 is not thymosin beta-4

TB-500 is commonly discussed as though it were simply another name for thymosin beta-4. Chemically, that is not accurate. TB-500 refers to the synthetic, N-acetylated seven-amino-acid sequence Ac-Lys-Lys-Thr-Glu-Thr-Glu-Gln, usually written Ac-LKKTETQ. It is a short fragment, not the intact protein. The “Ac-” indicates an acetyl group at the N-terminus; it is part of the molecular description, not decorative shorthand.

Full-length Tβ4 contains 43 amino acids and has a much larger molecular mass, approximately 4,963 Da. The original biochemical work on Tβ4 established it as the principal G-actin-sequestering peptide in the system studied, but that paper examined full-length Tβ4 and its Fx designation, not the synthetic TB-500 fragment.¹ This difference in identity should appear at the beginning of any careful evidence summary, not as a footnote after claims about healing.

A useful comparison is the difference between a complete sentence and a seven-word excerpt. The excerpt may contain an important phrase, but its size, neighboring words, and context have changed. A fragment can have its own behavior, stability, distribution, and safety profile. Those possibilities cannot be resolved by relabeling results from the parent molecule. For background on how to keep a peptide’s name separate from what human evidence actually tests, see the related discussion of what BPC-157 is and its evidence boundaries.

What does actin sequestration mean?

Actin is a structural protein that cells can assemble into filaments. Those filaments help give a cell shape and participate in movement. “G-actin” means actin in its individual, globular form, before it is assembled into a filament. Sequestration means that a peptide binds some of those individual actin molecules and keeps them in a bound pool, rather than leaving every molecule immediately available for filament assembly.

That is a plain-language description of a biochemical interaction, not a promise that a wound will close or a tendon will regenerate. Safer, Elzinga, and Nachmias identified full-length Tβ4 and Fx as indistinguishable in their actin-sequestering behavior in the reported experiments.¹ The finding supports a mechanism to investigate for the full-length protein. It does not demonstrate that TB-500 has the same binding behavior, nor does it establish a clinical outcome for either molecule.

Mechanism is also not the same as treatment evidence. A laboratory observation can explain why researchers consider a molecule biologically interesting, while an animal model tests outcomes in an organism, and a controlled human study tests outcomes in people under defined conditions. Those are separate steps. The available packet gives substantial healing evidence for full-length Tβ4, but it does not supply a direct human TB-500 trial.

What research exists for full-length Tβ4?

The most important evidence-labeling rule is simple: the studies in this section used full-length thymosin beta-4, not TB-500. The 2016 review by Goldstein and Kleinman describes preclinical work in normal, diabetic, and aged animals, as well as burn models, and discusses phase 2 clinical trials involving pressure ulcers, stasis ulcers, and epidermolysis bullosa.² These findings make Tβ4 a subject of regenerative-medicine research. They do not become fragment data because both names contain “thymosin beta-4.”

The clinical results are more specific than the phrase “healing peptide” suggests. In a phase 2 double-blind randomized trial at eight European sites, 73 patients with venous stasis ulcers received topical full-length Tβ4 or placebo. Safety was comparable to placebo in the report. At the 0.03% dose studied, about 25% of small-to-moderate wounds were completely healed at three months.³ That result belongs to a particular full-length molecule, topical formulation, population, wound type, trial design, and follow-up period.

A separate review of animal models and two phase 2 randomized trials reported that, among patients who healed, full-length Tβ4 accelerated healing by approximately one month.⁴ “Among patients who healed” matters: it is not equivalent to saying that every participant healed, that every wound type responded, or that the result proves regeneration. The review itself does not turn its full-length Tβ4 studies into evidence for the TB-500 fragment.

This is why a responsible summary can say two things at once. Full-length Tβ4 has a meaningful preclinical and phase 2 research record in selected wound settings, including reported controlled human studies. And the same summary must say that those data did not study TB-500. For a broader guide to distinguishing human and animal claims, readers can compare this article with human research versus animal research.

Why parent-protein research cannot simply be transferred

The first problem is size and composition. Full-length Tβ4 is a 43-residue protein; TB-500 is a seven-residue synthetic fragment with an N-terminal acetyl group. Changing a molecule’s length and chemical ends changes the object being tested. A result for one structure is not a result for another structure unless that second structure has been tested and the comparison has been justified.

The second problem is cleavage. Full-length Tβ4 can produce the N-terminal cleavage product Ac-SDKP.² TB-500 is the Ac-LKKTETQ fragment and does not contain the full-length protein’s N-terminal region that produces Ac-SDKP. Therefore, mechanisms or effects that depend on the parent protein, its complete sequence, or products generated from its N-terminal region may not transfer to TB-500. This is not a claim that every Tβ4 finding depends on Ac-SDKP; it is a reason not to assume that all parent-protein biology survives truncation.

The third problem is evidence design. Full-length Tβ4 trials used a particular topical drug product and studied defined ulcers. Even if two molecules eventually showed a related laboratory action, the exposure, formulation, tissue distribution, and clinical endpoint would still need separate evaluation. The full-length Tβ4 reviews do not provide that evaluation for TB-500.²⁴

What is known about human TB-500 exposure?

According to the FDA’s compounding safety information, the agency has not identified human exposure data for drug products containing thymosin beta-4, fragment (LKKTETQ), the substance identified there as TB-500. The FDA says it lacks important information about safety issues, including whether the fragment would cause harm if administered to humans.⁵ That is the central human-data conclusion for this article.

The FDA also identifies a potential immunogenicity concern related to aggregation and peptide-related impurities.⁵ This is a safety uncertainty, not evidence that harm has been demonstrated in a TB-500 trial. Conversely, “no identified human exposure data” is not evidence that the fragment is safe. Both overstatement and reassurance would go beyond the verified record.

Consequently, there are no direct human TB-500 efficacy results in the evidence packet to summarize, and no basis here for inventing a trial, treatment success rate, or human safety profile. Full-length Tβ4’s phase 2 findings should remain labeled as full-length Tβ4 findings. The FDA’s fragment-specific warning should remain labeled as fragment-specific. Keeping those labels intact is more informative than combining them into a single marketing-style narrative.

The bottom line

TB-500 is the synthetic Ac-LKKTETQ heptapeptide, not full-length thymosin beta-4. Full-length Tβ4 has an actin-sequestration literature, animal wound-healing research, and selected phase 2 human studies. Those results are scientifically relevant background, but they are not direct TB-500 evidence. TB-500 is chemically shorter, does not generate the parent protein’s Ac-SDKP cleavage product, and has no identified human exposure data according to the FDA. The most defensible conclusion is uncertainty, not proven repair and not proven safety.

Readers looking at commercial claims should ask which exact molecule was studied, whether the cited paper used full-length Tβ4 or Ac-LKKTETQ, what formulation and route were used, and whether the endpoint was measured in cells, animals, or people. Those questions make it easier to separate research literacy from practical treatment advice. For adjacent, evidence-focused reading, visit the full articles collection, or explore the contextual books Glow Stack and Repair Protocol.

Frequently asked questions

References

1. Safer D, Elzinga M, Nachmias VT. “Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable.” Journal of Biological Chemistry, 1991;266(7):4029–4032. PMID 1999398 ↗
2. Goldstein AL, Kleinman HK. “Thymosin β4 Promotes Dermal Healing.” Advances in Wound Care (New Rochelle), 2016;5(11):501–511. PMID 27450738 ↗
3. Guarnera G, DeRosa A, Camerini R, et al. “The effect of thymosin treatment of venous ulcers.” Annals of the New York Academy of Sciences, 2010;1194:207–212. PMID 20536470; doi:10.1111/j.1749-6632.2010.05490.x ↗
4. Treadwell T, Kleinman HK, Crockford D, Hardy MA, Guarnera GT, Goldstein AL. “The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients.” Annals of the New York Academy of Sciences, 2012;1270:37–44. PMID 23050815; doi:10.1111/j.1749-6632.2012.06717.x ↗
5. U.S. Food and Drug Administration. “Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks.” FDA drug compounding safety information ↗

This article is for educational purposes and is not medical advice.